“Top-notch science that leads to a treatment” Story … of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 (LCA10) patients, has progressed steadily. The … March 31, 2017
Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 News update Top-line results showed the Illuminate study did not meet its primary endpoint or secondary endpoints. We will continue to analyze the data. February 11, 2022
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 Press release … Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, Netherlands & CAMBRIDGE, Mass., April … April 13, 2021
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen Press release … 2/3 Illuminate trial of sepofarsen for CEP290 -mediated Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation, also … January 04, 2022
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO) Press release … trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: Stephen R. Russell, MD, … November 02, 2020
ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Press release … call on July 20, 2020 at 5:00 pm EDT, which will focus on Leber congenital amaurosis 10 (LCA10) and the investigational RNA therapy for … July 13, 2020
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients Press release … trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the … October 10, 2019
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial Press release QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events September 05, 2018
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10 Press release Key Updates May 31, 2017
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO) Press release … (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 … June 08, 2020